Auph short interest.

Sep 27, 2023 · Aurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ...

Auph short interest. Things To Know About Auph short interest.

AUPH fails-to-deliver data, short interest, short sale transactions, short volume, borrow rates, short shares availability and much more information. Help Login Register Trading System Live Account. Ticker: ... AUPH. Trading System Performance for AUPH. Appeared in Fisher Transform Cross Up screen on 2023-02-17 2023-02-08: Short Sale Restricted ...Biocept, Inc. (NASDAQ:BIOC – Get Free Report) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totalling 26,500 shares, a decline of 6.7% from the June 30th total of 28,400 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average […]WebAurinia Pharmaceuticals Inc (NASDAQ: AUPH) has seen a decrease in hedge fund interest in recent months. Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was in 24 hedge funds' portfolios at the end of ...Nursing is an excellent career path if you’re interested in working in the healthcare industry and strive to provide quality care to patients. If you’re short on time or worry that attending a brick-and-mortar school isn’t possible, one alt...

A high-level overview of Aurinia Pharmaceuticals Inc. (AUPH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. ... Short Interest ...Mission Statement. The mission of ShortSqueeze® is to provide short interest stock market data and services, so our members will be better informed of short selling in the market, track short interest in stocks, and gain from the advantages of this powerful market data. Tuesday November 28, 2023. 20 Min Delayed.

Biocept, Inc. (NASDAQ:BIOC – Get Free Report) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totalling 26,500 shares, a decline of 6.7% from the June 30th total of 28,400 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average […]WebBiocept, Inc. (NASDAQ:BIOC – Get Free Report) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totalling 26,500 shares, a decline of 6.7% from the June 30th total of 28,400 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average […]Web

Find out why interest in selling AUPH stock has not subsided in some quarters. ... @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 ...Based on recent acquisitions, Aurinia ( AUPH) would be more likely to see $18–$20 per share in a takeover, RBC analyst Douglas Miehm, who has an outperform rating with a $13 price target on AUPH ...The setup was perfect (IMO) with more than 21% Short Interest, a Put/Call ratio of 0.25 (Dec-2023) and a strong earnings + guidance from a grossly oversold position. Long term Bullish, but I will be waiting for the $3.29 gap fill most likely to re-build, unless the Company can formalize a plan to be NASDAQ compliant in short-order. 1969: CARVA high-level overview of Aurinia Pharmaceuticals Inc. (AUPH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …

Aurinia Pharmaceuticals (AUPH, $9.25) price may drop as it broke higher Bollinger Band on Nov 20, 2023 Tickeron - Technical Analysis • 6 days ago. This price move could be a signal that AUPH may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Aurinia Pharmaceuticals last released its quarterly earnings results on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. The business earned $54.52 million during the quarter, compared to the consensus estimate of $38.41 million.

High short interest. Together with FinMasters. See AUPH options chain. ... AUPH quarterly revenue growth was 59.10%, higher than the industry and sector average revenue growth (0.75% and 2.15%, respectively). See AUPH revenue growth chart. AUPH profitability is improving. The YoY profit margin change was 3006.43 percentage points.The average of price targets set by Wall Street analysts indicates a potential upside of 46.1% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the ...AUPH ($8.23) is undervalued by 7.05% relative to our estimate of its Fair Value price of $8.85 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safetyThis page provides short interest, short volume, short volume ratio, short borrow rates, and short squeeze score for the security. US: AUPH / Aurinia Pharmaceuticals Inc - Insider Trading Report This page provides data on the corporate insiders of Aurinia Pharmaceuticals Inc and their trades, trade performance, and predictive analysis.For 2022, Aurinia ( AUPH) projects net revenue from sales of Lupkynis to reach $115M-135M. Several days ago, shares of the company surged in reaction to upbeat remarks made by CEO on its sales ...Aurinia Pharmaceuticals ( NASDAQ: AUPH) rose 6.5% amid renewed takeover speculation. There's speculation than unnamed suitor may be eyeing a takeover of Aurinia ( AUPH ), according to a Betaville ...Arrow Financial Co. (NASDAQ:AROW – Get Rating) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 153,000 shares, an increase of 13.1% from the February 28th total of 135,300 shares. Based on an average trading volume of 34,700 shares, the […]Web

AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Nov 24, 2023 · Short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) saw shorts transact 17.28 million shares and set a 9.89 days time to cover. Analysts on Wall Street suggest a consensus price target of $13.21, implying an increase of 29.75% to the stock’s recent value. Short Interest. Percentage of Shares Shorted 11.97% of the outstanding shares of Aurinia Pharmaceuticals have been sold short. Short Interest Ratio / Days to Cover Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 9.2. Change versus previous monthJul 4, 2022 · Still, when we talk about a small-cap biotech that is clearly drawing the interest of some big pharma guys, we can say that AUPH's current valuation is very low, without but surely with buyout ... May 22, 2023 · @PITX3 not really great short squeeze potential, more like short caress. 11% of float takes 5 - 6 days to cover. From mid-April to mid-May the short position decreased by 2M down to 15.5M, 11% of ...

Aurinia ( AUPH) shares have climbed ~59.7% in the year so far despite a ~2% decline over the past 30 days. The stock has added ~5.8% in the post-market with ~1.5M shares changing hands compared to ...AUPH 4.86%. Apple Inc. $191.24. AAPL 0.68%. Sarepta Therapeutics Inc. ... Earnings before interest, taxes, depreciation, and amortization, is a measure of a company's overall financial performance ...

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AUPH / Aurinia Pharmaceuticals Inc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. Author: u/Yolteotl (Karma: 16452, Created: Feb-2013). AUPH: Best treatment against Lupus nephritis, still widely undervalued, buyout candidate and…NP. VQNPX - Vanguard Growth and Income Fund Investor Shares This fund is a listed as child fund of Vanguard Group Inc and if that institution has disclosed ownership in this security, then these positions will not be double counted when calculating total shares and total value. 28,200. -40.63.A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DAWN shares currently have a short interest ratio of 15.0. Learn More on Day One Biopharmaceuticals's short interest ratio.Nov 21, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) soared 6.7% amid takeover speculation. The Aurinia ( AUPH) stock surge comes amid a report that a Gilead Sciences ( GILD) corporate jet made a trip to ... Live Short Interest data, Utilization, Cost to borrow and much more for Aurinia Pharmaceuticals Inc., Nasdaq:AUPH

A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. DAWN shares currently have a short interest ratio of 15.0. Learn More on Day One Biopharmaceuticals's short interest ratio.

AUPH Short Positions, Funds Shorting Aurinia Pharmaceuticals Inc ... Short Interest Funds Shorting AUPH Short Transactions Short Volume Fails to Deliver. Options . Options Chain Options Sentiment Options Flow Gamma Exposure Implied Volatility. Filings . SEC Filings - Categorized SEC Filings - Latest Press Releases Exhibits. Financials .

Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...In Leo Tolstoy’s short story “What Men Live By,” the angel Michael learns that people dwell best when in love and that they do not always know what is in their best interests. Michael also learns that people live best by loving others and n...The largest shareholder of Aurinia Pharmaceuticals (NASDAQ:AUPH) said it plans to withholder support for seven board members at the company's upcoming annual meeting. Iljin SNT, which has a 6.1% ...Short term loan lenders offer loans based on current income or assets and not one’s credit score. Because of this many people choose to get a short title loan when they’re in need of money.M&A season started earlier this week with TRIL / Pfizer, AUPH is one of the best candidate for the big pharmas. A weird Press Release appeared yesterday morning on different websites, likely fake or at least released to early, about a 35+ acquisition by a big pharma, it was later asked to be removed from Benzinga (but not denied) The short interest Short Sale Transactions - Last 7 Days and Value >= $5000 Due to the enormous number of transactions, we currently only display transactions where the transaction value is greater than or equal to $5000.00.Nov 29, 2023 · AUPH | Complete Aurinia Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ... Short Interest 17.19M 11/15/23 % of Float ... AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...Short Interest. Prev. Close. Compare to Peers. More on AUPH. Trending Analysis. Trending News. Seeking Alpha - Power to Investors. Power to Investors. Follow us. Download app. Subscription Support ...The short interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is 17.19 million shares and it means that shorts have 11.64 day(s) to cover. The consensus price target of analysts on Wall Street is $13.21, which implies an …This short interest tracker provides a variety of short interest related data, sourced from a variety of partners. The data is organized by …Aurinia Pharmaceuticals (AUPH, $9.25) price may drop as it broke higher Bollinger Band on Nov 20, 2023 Tickeron - Technical Analysis • 6 days ago. This price move could be a signal that AUPH may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

1K subscribers in the AUPH community. A place to discuss Aurinia Pharmaceuticals, Inc.Aurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ...Nov 21, 2023 · Aurinia Pharmaceuticals ( NASDAQ: AUPH) soared 6.7% amid takeover speculation. The Aurinia ( AUPH) stock surge comes amid a report that a Gilead Sciences ( GILD) corporate jet made a trip to ... Instagram:https://instagram. mazda stockswsj cfo journalwells fargo bank refinancemortgage lender orlando The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ...Aug 24, 2022 · Approximately 10% of the overall float is currently held short. Two directors bought a collective 10,000 shares in early March. Prior to that several insiders sold just over $1.2 million worth of ... lithium americas newsjpmorgan crypto wallet AUPH - Short squeeze stock short interest data and short selling information for shares of Aurinia Pharmaceuticals Ord. Short interest stock data available for NASDAQ, NYSE, …Dec 2, 2021 · Aurinia Pharmaceuticals (AUPH) rose 17% at least partly on some take takeover speculation following comments from Novartis (NVS). Novartis reportedly said during its R&D day earlier... moat holdings The Whisper Report ® Grades Earnings Guidance Reactions Strategies Earnings Screener Short Interest ... AUPH. Aurinia Pharm Ord. $8.65. -0.52. -5.67%. Overview ...Aurinia Pharmaceuticals posted its second quarter numbers on August 3rd. The company posted a GAAP loss of 8 cents a share, more than a dime a share better than expectations. Revenues rose 47% on ...For fiscal 2023, the company expects LUPKYNIS revenue to be between $120 million and $140 million, representing annual growth of 15.4% to 34.6% in terms of net product sales. While analysts expect ...